Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Nicola Gokbuget

Gliwice Branch, 
Gliwice, SL, PL 
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
Gliwice Branch, 
Gliwice, SL, PL 
OverviewLocationsClinical Research

Overview

Nicola Gokbuget practices in Gliwice, Poland. Ms. Gokbuget is rated as an Experienced expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Burkitt Lymphoma, Adult T-Cell Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 147 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Gender
Female

Locations

Gliwice Branch, Gliwice, SL, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)
Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: Blinatumomab
Study Phase: Phase 2
An Open Label, Phase I/II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
An Open Label, Phase I/II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Blinatumomab, Venetoclax
Study Phase: Phase 1/Phase 2
A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)
A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Blinatumomab
Study Phase: Phase 2
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Dexamethasone, Prednisolone, Cytarabine, Idarubicin, Granulocyte-Colony-Stimulating Factor, Mercaptopurine, Methotrexate, Rituximab, HDARAC, Vincristine, Depocyte, Asparaginase
Study Phase: Phase 4
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 4
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
Enrollment Status: Completed
Publish Date: September 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

147 Total Publications

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Journal: Leukemia & lymphoma
Published: February 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gokbuget's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile